{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-129181","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.644279+00:00","generated_at":"2026-05-29T02:15:36.624909+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics awarded $9.5M CPRIT grant for MT-601 in pancreatic cancer study","bullets":["Received $9.5M non-dilutive grant from CPRIT to support Phase 1 PANACEA study of MT-601 in metastatic pancreatic cancer.","Also received $2M NIH SBIR grant; total non-dilutive funding exceeds $30M from FDA, NIH, and CPRIT.","Clinical program initiation for MT-601 in pancreatic cancer expected in 2025.","Preliminary data from prior multiTAA-specific T cell study showed 1 CR, 3 PRs, 6 SD in 13 pancreatic cancer patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-129181","json":"https://secwatch.observer/filing/0001104659-24-129181.json","markdown":"https://secwatch.observer/filing/0001104659-24-129181.md","text":"https://secwatch.observer/filing/0001104659-24-129181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924129181/0001104659-24-129181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924129181/tm2431191d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:15:36.624909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}